Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells

Cancer Investigation

Volumn 25, Issue 1, 2007, Pages 32-37

  Fujimoto, Naohiro ^a   Miyamoto, Hiroshi ^b   Mizokami, Atsushi ^c   Harada, Shuji ^a   Nomura, Masayoshi ^a   Ueta, Yoichi ^a   Sasaguri, Takakazu ^a   Matsumoto, Tetsuro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Androgen receptor; Cofactor; Hormone resistance; Prostate cancer; TNF

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN LNCAP; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; GENETIC TRANSCRIPTION; HORMONE RESISTANCE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR RECEPTOR COACTIVATOR 2; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947223234     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900601130698     Document Type: Article

References (29)

1. Petrylak, D.P.; Tangen, C.M.; Hussain, M.H.; et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351, 513-1520.
2. Tannock, I.F.; de Wit, R.; Berry, W.R.; et al. TAX 327 Investigators. docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351, 1502-1512.
3. Harada, S.; Keller, E.T.; Fujimoto, N.; et al. Long-term exposure of tumor necrosis factor α causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate 2001, 46, 319-326.
4. Fujimoto, N.; Mizokami, A.; Harada, S.; Matsumoto, T. Different expression of androgen receptor coactivators in human prostate. Urology 2001, 58, 289-294.
5. Mizokami, A.; Saiga, H.; Matsui, T.; Mita, T.; Sugita, A. Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. Endocrinol. Jpn. 1992, 39, 235-243.
6. Miyamoto, H.; Marwah, P.; Marwah, A.; Lardy, H. Chang, C. 3β-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc. Natl. Acad. Sci. USA 2003, 100, 4440-4444.
7. Chang, C.; Kokontis, J.; Liao, S. Structual analysis of complementary DNA and amino acid sequences of the human and rat androgen receptors. Proc. Natl. Acad. Sci. USA 1998, 85, 7211-7215.
8. Jester, G.; Trapman, J.; Brinkmann, A.O. Nuclear import of the androgen receptor. Biochem. J. 1993, 293, 761-768.
9. Zhou, Z.-X.; Sar, M.; Simenral, J.A.; Lane, M.V.; Wilson, E.M. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. J. Biol. Chem. 1994, 269, 13115-13123.
10. So, A.; Gleave, M.; Hurtado-Col, A.; Nelson, C. Mechanisms of the development of androgen independence in prostate cancer. World J. Urol. 2005, 23, 1-9.
11. Edwards, J.; Krishna, N.S.; Grigor, K.M.; Bartlett, L.M.S. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer. 2003, 89, 552-556.
12. Chen, C.D.; Welsbier, D.S.; Tran, C.; et al. Molecular determinations of resistance to antiandrogen therapy. Nat. Med. 2004, 10, 33-39.
13. Gregory, C.W.; Johnson, R.T.; Mohler, J.L.; French, F.S.; Wilson, E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001, 61, 2892-2898.
14. Hu, Y.C.; Yeh, S.; Yeh, S.D.; et al. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J. Biol. Chem. 2004, 279, 33438-33446.
15. Buchanan, G.; Yang, M.; Harris, J.M.; et al. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol. Endocrinology 2001, 15, 46-56.
16. Shibata, H.; Spencer, T.E.; Onate, S.A.; et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent. Prog. Horm. Res. 1997, 52, 141-165.
17. Fujimoto, N.; Yeh, S.; Kang, H.; et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J. Biol. Chem. 1999, 274, 8316-8321.
18. Kang, H.; Yeh, S.; Fujimoto, N.; Chang, C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with androgen receptor. J. Biol. Chem. 1999, 274, 8570-8576.
19. Bevan, C.L.; Hoare, S.; Claessens, F.; Heery, D.M.; Parker, M.G. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol. Cell. Biol. 1999, 19, 8383-8392.
20. Voegel, J.J.; Heine, M.J.S.; Zechel, C.; Chambon, P.; Gronemeyer, H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 1996, 15, 3667-3675.
21. Yeh, S.; Chang, C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc. Natl. Acad. Sci. USA 1996, 93, 5517-5521.
22. Li, H.; Gomes, P.J.; Chen, J.D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc. Natl. Acad. Sci. USA 1997, 94, 8479-8484.
23. Muller, J.N.; Isele, U.; Metzger, E.; et al. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J. 2000, 19, 359-369.
24. Agoulnik, I.U.; Krause, W.C.; Bingman, W.E.; 3rd; et al. Repressors of androgen and progesterone receptor action. J. Biol. Chem. 2003, 278, 31136-31148.
25. Linja, M.J.; Porkka, K.P.; Kang, Z.; et al. Expression of androgen receptor coregulators in prostate caner. Clin. Cancer Res. 2004, 10, 1032-1040.
26. Gregory, C.W.; He, B.; Johnson, R.T.; et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001, 61, 4315-4319.
27. Nishimura, K.; Ting, H.J.; Harada, Y.; et al. Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res. 2003, 63, 4888-4894.
28. Gregory, C.W.; Hamil, K.G.; Kin, D.; et al. Androgen receptor expression in androgen independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res. 1998, 58, 5718-5724.
29. Michalaki, V.; Syrigos, K.; Charles, P.; Waxman, J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer 2004, 90, 2312-2316.